VISEN Pharmaceuticals

Direct answer

VISEN Pharmaceuticals is publicly traded on HKSE under the ticker 2561.HK.

VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP...

Can you invest in VISEN Pharmaceuticals?

Yes. VISEN Pharmaceuticals is publicly traded on HKSE under the ticker 2561.HK.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for VISEN Pharmaceuticals

Detailed equity research is provided by MarketSnap.